KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Accured Expenses: 2018-2025

Historic Change in Accured Expenses for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $199.0 million.

  • Moderna's Change in Accured Expenses rose 306.12% to $199.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$166.0 million, marking a year-over-year increase of 79.71%. This contributed to the annual value of -$385.0 million for FY2024, which is 13.24% down from last year.
  • Per Moderna's latest filing, its Change in Accured Expenses stood at $199.0 million for Q3 2025, which was up 1,521.43% from -$14.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Change in Accured Expenses ranged from a high of $696.0 million in Q3 2023 and a low of -$1.1 billion during Q4 2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$66.0 million (2024), whereas its average is -$83.7 million.
  • In the last 5 years, Moderna's Change in Accured Expenses soared by 2,475.00% in 2021 and then crashed by 534.21% in 2023.
  • Moderna's Change in Accured Expenses (Quarterly) stood at $389.0 million in 2021, then slumped by 381.23% to -$1.1 billion in 2022, then surged by 63.16% to -$403.0 million in 2023, then spiked by 107.44% to $30.0 million in 2024, then spiked by 306.12% to $199.0 million in 2025.
  • Its Change in Accured Expenses was $199.0 million in Q3 2025, compared to -$14.0 million in Q2 2025 and -$381.0 million in Q1 2025.